CABA
Cabaletta Bio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Consensus Rating "Buy"
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CABA
Cabaletta Bio, Inc.
A clinical-stage biotech company focused on targeted cell therapies for autoimmune diseases
2929 Arch Street, Suite 600, Philadelphia, PA 19104
--
Cabaletta Bio, Inc., was incorporated under the laws of the State of Delaware in April 2017. The company is a clinical-stage biotechnology company focused on discovering and developing engineered T-cell therapies that have the potential to provide a deep and durable, perhaps therapeutic, treatment for patients with autoimmune diseases.
Company Financials
EPS
CABA has released its 2025 Q3 earnings. EPS was reported at -0.44, versus the expected -0.46, beating expectations. The chart below visualizes how CABA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
